A lovely story and a happy ending for a young Cambodian orphan with hepatitis B.
By MATTHEW STOLLE, Post-Bulletin Posted July 19
When Chung Eang Lip was 7, his father took him to the market in Phnom Penh, Cambodia, and abandoned him.
For three days, Lip wandered the city’s streets, hungry and calling for his mother. Lip’s last memory from the ordeal was waking up and seeing his mom hovering over him.
“I was really sick. I didn’t have anything to eat for those three days. I only remember that when I opened my eyes, I saw my mom and that’s all,” said Lip, whose mom took him back to their rural home.
By 13, both of Lip’s parents were dead, and he was largely on his own, living with an older brother. What most people regard as normal family life — or what passed for it in Lip’s life — was largely a thing of the past.
Or so he thought.
Read more of this touching story here.
Congressional briefing organized by the Deadliest Cancers Coalition with the Congressional Caucus on Deadliest Cancers, Thursday, June 19, 2014, Washington, DC
Recent projections for the top cancer killers in 2030 confirmed some encouraging trends but also sounded a warning bell. Continue reading
This informative article from Internal Medicine News, July 1, 2014, analyzes two studies from the July issue of Gastroenterology, and looks at the impact of antivirals on the incidence of liver cancer, the need for liver transplantation and the risk of death in chronic HBV patients. The potency of the antiviral made a significant difference and supported current practice guidelines recommending the use of entecavir and tenofovir as first line drugs for the treatment of chronic HBV. Be sure to also read the accompanying editorial by Dr. George Papatheodoridis.
Internal Medicine News Digital Network, July 1, 2014, article written by DENISE NAPOLI.
Nucleoside analogues are effective at preventing hepatocellular carcinoma in hepatitis B, but all are not equal when it comes to overall mortality and liver transplant, according to two new studies in the July issue of Gastroenterology.
In the first study, Dr. Chun-Ying Wu of the National Yang-Ming University, in Taipei, Taiwan, and his colleagues examined the long-term protective effects of nucleoside analogue therapy among chronic hepatitis B patients (doi.org/10.1053/j.gastro.2014.03.048).
They conducted a retrospective nationwide cohort study using data from Taiwan’s National Health Insurance Research Database, collecting records from 1997 through 2010 on patients with chronic hepatitis B.
Click here to read Internal Medicine News article and editorial in its entirety.
A recent analysis of studies that looked at the benefits of screening concluded that the evidence remains insufficient to make a strong case for or against screening. The authors of an accompanying editorial did note, however, that screening has a much greater potential to be beneficial in the highest-risk patients, and it is appropriate to allow clinicians caring for these patients to continue to offer screening. Clearly, more data are needed.
Although current liver cancer screening methods are not perfect, the Hepatitis B Foundation encourages liver cancer screening. Early detection can give patients more treatment options, and potentially a greater chance of successful treatment. Screening does save lives.
Roxanne Nelson, Medscape, June 19, 2014, reports on study published online June 16 in the Annals of Internal Medicine.
When looking at the effects of screening on mortality, 2 clinical trials and 18 observational studies provided very-low-strength evidence from which to draw conclusions about the mortality effects of HCC screening, as compared with no screening.
Both of the trials were conducted in China in areas with high HCC prevalence, and most participants had hepatitis B with or without cirrhosis. One of the trials (n = 9757) offered serum α-fetoprotein testing and ultrasonography every 6 months, and participants in the control group (n = 9443) were not made aware of the study or actively followed. HCC mortality was less frequent in the screened group (83.2 vs 131.5 per 100,000 person-years; rate ratio, 0.63).
Read article in its entirety here.